Medical College of Wisconsin
CTSICores SearchResearch InformaticsREDCap

Publications indexed to the term Chemotherapy, Adjuvant

1Evaluation of Adjuvant Chemotherapy Survival Outcomes Among Patients With Surgically Resected Pancreatic Carcinoma With Node-Negative Disease After Neoadjuvant Therapy. (Hammad AY, Hodges JC, AlMasri S, Paniccia A, Lee KK, Bahary N, Singhi AD, Ellsworth SG, Aldakkak M, Evans DB, Tsai S, Zureikat A) JAMA Surg 2023 Jan 01;158(1):55-62    
1Patterns of Adjuvant Chemotherapy Use and Association With Survival in Adults 80 Years and Older With Pancreatic Adenocarcinoma. (Mehtsun WT, McCleary NJ, Maduekwe UN, Wolpin BM, Schrag D, Wang J) JAMA Oncol 2022 Jan 01;8(1):88-95       5 Citations
2Invasive Breast Cancer Treatment Patterns in Women Age 80 and Over: A Report from the National Cancer Database. (Frebault J, Bergom C, Cortina CS, Shukla ME, Zhang Y, Huang CC, Kong AL) Clin Breast Cancer 2022 Jan;22(1):49-59       4 Citations
2Ten-year experience in optimizing neoadjuvant therapy for localized pancreatic cancer-Medical college of Wisconsin perspective. (Ward EP, Evans DB, Tsai S) J Surg Oncol 2021 May;123(6):1405-1413       2 Citations
2Prognostic Outcomes of Signet Ring Cell Carcinoma of the Breast. (Mehdi M, Kong AL, Frebault J, Huang S, Huang CC, Cortina CS) J Surg Res 2021 Aug;264:138-148       2 Citations
4Adjuvant therapy rates and overall survival in patients with localized pancreatic cancer from high Area Deprivation Index neighborhoods. (Mora J, Krepline AN, Aldakkak M, Christians KK, George B, Hall WA, Erickson BA, Kulkarni N, Evans DB, Tsai S) Am J Surg 2021 Jul;222(1):10-17       24 Citations
1Early stage triple negative breast cancer: Management and future directions. (Chaudhary LN) Semin Oncol 2020 Aug;47(4):201-208       18 Citations
1Adrenalectomy for Secondary Malignancy: Patients, Outcomes, and Indications. (Wachtel H, Roses RE, Kuo LE, Lindeman BM, Nehs MA, Tavakkoli A, Parangi S, Hodin RA, Fraker DL, James BC, Carr AA, Wang TS, Solórzano CC, Lubitz CC) Ann Surg 2021 Dec 01;274(6):1073-1080       8 Citations
1Effects of Previous Medication Regimen Factors and Bipolar and Psychotic Disorders on Breast Cancer Endocrine Therapy Adherence. (Haskins CB, Neuner JM, McDowell BD, Carnahan RM, Fiedorowicz JG, Wallace RB, Smith BJ, Chrischilles EA) Clin Breast Cancer 2020 Jun;20(3):e261-e280       1 Citation
3A high mitotic score in breast cancer after neoadjuvant chemotherapy is predictive of outcome and associated with a distinct morphology. (Arispe Angulo KR, Jawa Z, Visotcky A, Majidi SS, Chitambar CR, Jorns JM) Histopathology 2020 Apr;76(5):661-670    
2Trends in the Use of Adjuvant Chemotherapy for High-Grade Truncal and Extremity Soft Tissue Sarcomas. (Squires MH, Ethun CG, Suarez-Kelly LP, Yu PY, Hughes TM, Shelby RD, Tran TB, Poultsides G, Charlson J, Gamblin TC, Tseng J, Roggin KK, Chouliaras K, Votanopoulos K, Krasnick BA, Fields RC, Pollock RE, Grignol V, Cardona K, Howard JH) J Surg Res 2020 Jan;245:577-586       1 Citation
4Use of Neoadjuvant Chemotherapy in the Treatment of Locally Advanced Rectal Cancer. (Hu KY, Simpson MT, Blank JJ, Szabo A, Eastwood D, Ludwig KA, Peterson CY, Ridolfi TJ) J Surg Res 2019 Nov;243:447-452       10 Citations
6The association of pharmacy fill synchronization with breast cancer endocrine therapy adherence. (Neuner JM, Fergestrom NM, Laud PW, Nattinger AB, Beyer KMM, Flynn KE, Pezzin LE) Cancer 2019 Nov 15;125(22):3960-3965       3 Citations
1Assessing the Role of Neoadjuvant Chemotherapy in Primary High-Risk Truncal/Extremity Soft Tissue Sarcomas: An Analysis of the Multi-institutional U.S. Sarcoma Collaborative. (Zaidi MY, Ethun CG, Tran TB, Poultsides G, Grignol VP, Howard JH, Bedi M, Mogal H, Tseng J, Roggin KK, Chouliaras K, Votanopoulos K, Krasnick B, Fields RC, Oskouei S, Reimer N, Monson D, Maithel SK, Cardona K) Ann Surg Oncol 2019 Oct;26(11):3542-3549       16 Citations
1Folate as an Adjuvant Therapy in Methanol Poisoning. (Theobald J, Lim C) Nutr Clin Pract 2019 Aug;34(4):521-527       6 Citations
3The role of radiation therapy and margin width in localized soft-tissue sarcoma: Analysis from the US Sarcoma Collaborative. (Gannon NP, King DM, Ethun CG, Charlson J, Tran TB, Poultsides G, Grignol V, Howard JH, Tseng J, Roggin KK, Votanopoulos K, Krasnick B, Fields RC, Cardona K, Bedi M) J Surg Oncol 2019 Sep;120(3):325-331       14 Citations
1Predictors of swallow function after transoral surgery for locally advanced oropharyngeal cancer. (Gross JH, Townsend M, Hong HY, Miller E, Kallogjeri D, Zenga J, Pipkorn P, Jackson RS, Haughey B, Rich JT) Laryngoscope 2020 Jan;130(1):94-100       6 Citations
2Myeloid malignancies after treatment for solid tumours. (Guru Murthy GS, Abedin S) Best Pract Res Clin Haematol 2019 Mar;32(1):40-46       7 Citations
1Call for improved design and reporting in soft tissue sarcoma studies: A systematic review and meta-analysis of chemotherapy and survival outcomes in resectable STS. (Istl AC, Ruck JM, Morris CD, Levin AS, Meyer CF, Johnston FM) J Surg Oncol 2019 Jun;119(7):824-835       11 Citations
1Selection of Patients With Localized Extremity Soft Tissue Sarcoma for Treatment With Perioperative Chemotherapy. (Charlson J) Curr Treat Options Oncol 2018 Oct 25;19(12):65       4 Citations
2Perioperative chemotherapy is not associated with improved survival in high-grade truncal sarcoma. (Yu PY, Beal EW, Hughes TM, Suarez-Kelly LP, Shelby RD, Ethun CG, Tran TB, Poultsides G, Charlson J, Gamblin TC, Tseng J, Roggin KK, Chouliaras K, Votanopoulos K, Krasnick BA, Fields RC, Pollock RE, Grignol V, Cardona K, Howard JH) J Surg Res 2018 Nov;231:248-256       2 Citations
1The association of socioeconomic status with receipt of neoadjuvant chemotherapy. (Neuner JM, Kong A, Blaes A, Riley D, Chrischilles E, Smallwood A, Lizarraga I, Schroeder M) Breast Cancer Res Treat 2019 Jan;173(1):179-188       9 Citations
6A Phase II Clinical Trial of Molecular Profiled Neoadjuvant Therapy for Localized Pancreatic Ductal Adenocarcinoma. (Tsai S, Christians KK, George B, Ritch PS, Dua K, Khan A, Mackinnon AC, Tolat P, Ahmad SA, Hall WA, Erickson BA, Evans DB) Ann Surg 2018 Oct;268(4):610-619       52 Citations
1Are Providers and Patients Following Hormonal Therapy Guidelines for Patients Over the Age of 70? The Influence of CALGB 9343. (Cortina CS, Agarwal S, Mulder LL, Poirier J, Rao R, Ansell DA, Madrigrano A) Clin Breast Cancer 2018 Dec;18(6):e1289-e1292       7 Citations
1Pleomorphic Lobular Carcinoma In Situ: Imaging Features, Upgrade Rate, and Clinical Outcomes. (Savage JL, Jeffries DO, Noroozian M, Sabel MS, Jorns JM, Helvie MA) AJR Am J Roentgenol 2018 Aug;211(2):462-467       11 Citations
9Repurposing existing medications as cancer therapy: design and feasibility of a randomized pilot investigating propranolol administration in patients receiving hematopoietic cell transplantation. (Knight JM, Kerswill SA, Hari P, Cole SW, Logan BR, D'Souza A, Shah NN, Horowitz MM, Stolley MR, Sloan EK, Giles KE, Costanzo ES, Hamadani M, Chhabra S, Dhakal B, Rizzo JD) BMC Cancer 2018 May 24;18(1):593       19 Citations
1The Effect of Topoisomerase I Inhibitors on the Efficacy of T-Cell-Based Cancer Immunotherapy. (McKenzie JA, Mbofung RM, Malu S, Zhang M, Ashkin E, Devi S, Williams L, Tieu T, Peng W, Pradeep S, Xu C, Zorro Manrique S, Liu C, Huang L, Chen Y, Forget MA, Haymaker C, Bernatchez C, Satani N, Muller F, Roszik J, Kalra A, Heffernan T, Sood A, Hu J, Amaria R, Davis RE, Hwu P) J Natl Cancer Inst 2018 Jul 01;110(7):777-786       53 Citations
1Considerations for sentinel lymph node biopsy in breast cancer patients with biopsy proven axillary disease prior to neoadjuvant treatment. (Qu LT, Peters S, Cobb AN, Godellas CV, Perez CB, Vaince FT) Am J Surg 2018 Mar;215(3):530-533       6 Citations
1Risk of cancer death by comorbidity severity and use of adjuvant chemotherapy among women with locoregional breast cancer. (Kimmick GG, Li X, Fleming ST, Sabatino SA, Wilson JF, Lipscomb J, Cress R, Bergom C, Anderson RT, Wu XC, Written on behalf of the Center for Disease Control and Prevention National Program of Cancer Registry Patterns of Care Study Group) J Geriatr Oncol 2018 May;9(3):214-220       19 Citations
1Triple-Negative Breast Cancer: Who Should Receive Neoadjuvant Chemotherapy? (Chaudhary LN, Wilkinson KH, Kong A) Surg Oncol Clin N Am 2018 Jan;27(1):141-153       72 Citations
1Recurrent gastrointestinal bleeding in a patient with IgM paraproteinaemia. (de Mel S, Abid MB, Poon KS, Ng SY, Poon LM, Wang S) J Clin Pathol 2018 Mar;71(3):284-285    
1American Brachytherapy Society recurrent carcinoma of the endometrium task force patterns of care and review of the literature. (Kamrava M, Beriwal S, Erickson B, Gaffney D, Jhingran A, Klopp A, Park SJ, Viswanathan A, Yashar C, Lin L) Brachytherapy 2017;16(6):1129-1143       20 Citations
2Socioeconomic status and breast cancer treatment. (Dreyer MS, Nattinger AB, McGinley EL, Pezzin LE) Breast Cancer Res Treat 2018 Jan;167(1):1-8       74 Citations
1Transoral Resection of Human Papillomavirus (HPV)-Positive Squamous Cell Carcinoma of the Oropharynx: Outcomes with and Without Adjuvant Therapy. (Jackson RS, Sinha P, Zenga J, Kallogjeri D, Suko J, Martin E, Moore EJ, Haughey BH) Ann Surg Oncol 2017 Nov;24(12):3494-3501       20 Citations
1Trials in head and neck oncology: Evolution of perioperative adjuvant therapy. (Zenga J, Pipkorn P, Adkins DR, Thorstad WL, Nussenbaum B) Oral Oncol 2017 Sep;72:80-89       3 Citations
1Pathologic and Treatment Outcomes Among a Geriatric Population of Endometrial Cancer Patients: An NRG Oncology/Gynecologic Oncology Group Ancillary Data Analysis of LAP2. (Bishop EA, Java JJ, Moore KN, Walker JL) Int J Gynecol Cancer 2017 May;27(4):730-737       12 Citations
1Outcomes of surgically treated human papillomavirus-related oropharyngeal squamous cell carcinoma with N3 disease. (Zenga J, Haughey BH, Jackson RS, Adkins DR, Aranake-Chrisinger J, Bhatt N, Gay HA, Kallogjeri D, Martin EJ, Moore EJ, Paniello RC, Rich JT, Thorstad WL, Nussenbaum B) Laryngoscope 2017 Sep;127(9):2033-2037       6 Citations
5Preoperative Radiation Therapy Followed by Reexcision May Improve Local Control and Progression-Free Survival in Unplanned Excisions of Soft Tissue Sarcomas of the Extremity and Chest-Wall. (Saeed H, King DM, Johnstone CA, Charlson JA, Hackbarth DA, Neilson JC, Bedi M) Int J Surg Oncol 2016;2016:5963167       20 Citations
1Preoperative Therapy and Pancreatoduodenectomy for Pancreatic Ductal Adenocarcinoma: a 25-Year Single-Institution Experience. (Cloyd JM, Katz MH, Prakash L, Varadhachary GR, Wolff RA, Shroff RT, Javle M, Fogelman D, Overman M, Crane CH, Koay EJ, Das P, Krishnan S, Minsky BD, Lee JH, Bhutani MS, Weston B, Ross W, Bhosale P, Tamm EP, Wang H, Maitra A, Kim MP, Aloia TA, Vauthey JN, Fleming JB, Abbruzzese JL, Pisters PW, Evans DB, Lee JE) J Gastrointest Surg 2017 Jan;21(1):164-174       104 Citations
3Is long-term survival possible after margin-positive resection of retroperitoneal sarcoma (RPS)? (Klooster B, Rajeev R, Chrabaszcz S, Charlson J, Miura J, Bedi M, Gamblin TC, Johnston F, Turaga KK) J Surg Oncol 2016 Jun;113(7):823-7       10 Citations
3Safety and Efficacy of Minimally Invasive Acetabular Stabilization for Periacetabular Metastatic Disease with Thermal Ablation and Augmented Screw Fixation. (Hartung MP, Tutton SM, Hohenwalter EJ, King DM, Neilson JC) J Vasc Interv Radiol 2016 May;27(5):682-688.e1       37 Citations
1Outcomes of Adjuvant Mitotane after Resection of Adrenocortical Carcinoma: A 13-Institution Study by the US Adrenocortical Carcinoma Group. (Postlewait LM, Ethun CG, Tran TB, Prescott JD, Pawlik TM, Wang TS, Glenn J, Hatzaras I, Shenoy R, Phay JE, Keplinger K, Fields RC, Jin LX, Weber SM, Salem A, Sicklick JK, Gad S, Yopp AC, Mansour JC, Duh QY, Seiser N, Solorzano CC, Kiernan CM, Votanopoulos KI, Levine EA, Staley CA, Poultsides GA, Maithel SK) J Am Coll Surg 2016 Apr;222(4):480-90       61 Citations
1Prognostic factors modifying the treatment-free interval in recurrent ovarian cancer. (Eng KH, Hanlon BM, Bradley WH, Szender JB) Gynecol Oncol 2015 Nov;139(2):228-35       18 Citations
3Impact of chemotherapy on survival in surgically resected retroperitoneal sarcoma. (Miura JT, Charlson J, Gamblin TC, Eastwood D, Banerjee A, Johnston FM, Turaga KK) Eur J Surg Oncol 2015 Oct;41(10):1386-92       59 Citations
3Non-metastatic Pancreatic Cancer: Resectable, Borderline Resectable, and Locally Advanced-Definitions of Increasing Importance for the Optimal Delivery of Multimodality Therapy. (Evans DB, George B, Tsai S) Ann Surg Oncol 2015 Oct;22(11):3409-13       64 Citations
1SIGNIFICANT ELEVATION OF GROWTH HORMONE LEVEL IMPACTS SURGICAL OUTCOMES IN ACROMEGALY. (Anthony JR, Alwahab UA, Kanakiya NK, Pontell DM, Veledar E, Oyesiku NM, Ioachimescu AG) Endocr Pract 2015 Sep;21(9):1001-9       14 Citations
1Tocolytics used as adjunctive therapy at the time of cerclage placement: a systematic review. (Smith J, DeFranco EA) J Perinatol 2015 Aug;35(8):561-5       11 Citations
5Chemotherapy for Surgically Resected Intrahepatic Cholangiocarcinoma. (Miura JT, Johnston FM, Tsai S, George B, Thomas J, Eastwood D, Banerjee A, Christians KK, Turaga KK, Pawlik TM, Clark Gamblin T) Ann Surg Oncol 2015 Oct;22(11):3716-23       71 Citations
1Characterization of Anthropometric Changes that Occur During Neoadjuvant Therapy for Potentially Resectable Pancreatic Cancer. (Cooper AB, Slack R, Fogelman D, Holmes HM, Petzel M, Parker N, Balachandran A, Garg N, Ngo-Huang A, Varadhachary G, Evans DB, Lee JE, Aloia T, Conrad C, Vauthey JN, Fleming JB, Katz MH) Ann Surg Oncol 2015 Jul;22(7):2416-23       111 Citations
1Role of laparoscopy in patients with peritoneal metastases considered for cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC). (Jayakrishnan TT, Zacharias AJ, Sharma A, Pappas SG, Gamblin TC, Turaga KK) World J Surg Oncol 2014 Aug 21;12:270       45 Citations
1Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for malignant peritoneal mesothelioma: a systematic review and meta-analysis. (Helm JH, Miura JT, Glenn JA, Marcus RK, Larrieux G, Jayakrishnan TT, Donahue AE, Gamblin TC, Turaga KK, Johnston FM) Ann Surg Oncol 2015 May;22(5):1686-93       161 Citations
1ACR appropriateness Criteria® advanced stage endometrial cancer. (Elshaikh MA, Yashar CM, Wolfson AH, Cardenes HR, Erickson B, Jhingran A, Jolly S, Kidd E, Lee LJ, Mayr NA, Moore D, Rao GG, Small W Jr, Varia MA, Wahl AO, Yuh W, Gaffney DK, Expert Panel on Radiation Oncology-Gynecology:) Am J Clin Oncol 2014 Aug;37(4):391-6       11 Citations
1Comparison of swallowing function after intensity-modulated radiation therapy and conventional radiotherapy for head and neck cancer. (Pauloski BR, Rademaker AW, Logemann JA, Discekici-Harris M, Mittal BB) Head Neck 2015 Nov;37(11):1575-82       38 Citations
1Copper transporter CTR1 expression and tissue platinum concentration in non-small cell lung cancer. (Kim ES, Tang X, Peterson DR, Kilari D, Chow CW, Fujimoto J, Kalhor N, Swisher SG, Stewart DJ, Wistuba II, Siddik ZH) Lung Cancer 2014 Jul;85(1):88-93       58 Citations
1A nomogram to predict long-term survival after resection for intrahepatic cholangiocarcinoma: an Eastern and Western experience. (Hyder O, Marques H, Pulitano C, Marsh JW, Alexandrescu S, Bauer TW, Gamblin TC, Sotiropoulos GC, Paul A, Barroso E, Clary BM, Aldrighetti L, Ferrone CR, Zhu AX, Popescu I, Gigot JF, Mentha G, Feng S, Pawlik TM) JAMA Surg 2014 May;149(5):432-8       248 Citations
7Neoadjuvant FOLFIRINOX for borderline resectable pancreas cancer: a new treatment paradigm? (Christians KK, Tsai S, Mahmoud A, Ritch P, Thomas JP, Wiebe L, Kelly T, Erickson B, Wang H, Evans DB, George B) Oncologist 2014 Mar;19(3):266-74       160 Citations
1Low CHD5 expression activates the DNA damage response and predicts poor outcome in patients undergoing adjuvant therapy for resected pancreatic cancer. (Hall WA, Petrova AV, Colbert LE, Hardy CW, Fisher SB, Saka B, Shelton JW, Warren MD, Pantazides BG, Gandhi K, Kowalski J, Kooby DA, El-Rayes BF, Staley CA 3rd, Volkan Adsay N, Curran WJ, Landry JC, Maithel SK, Yu DS) Oncogene 2014 Nov 20;33(47):5450-6       17 Citations
1Treatment sequencing for resectable pancreatic cancer: influence of early metastases and surgical complications on multimodality therapy completion and survival. (Tzeng CW, Tran Cao HS, Lee JE, Pisters PW, Varadhachary GR, Wolff RA, Abbruzzese JL, Crane CH, Evans DB, Wang H, Abbott DE, Vauthey JN, Aloia TA, Fleming JB, Katz MH) J Gastrointest Surg 2014 Jan;18(1):16-24; discussion 24-5       152 Citations
1Managing malignant melanoma. (Dzwierzynski WW) Plast Reconstr Surg 2013 Sep;132(3):446e-460e       44 Citations
1Posterior reversible encephalopathy syndrome: more than meets the eye. (Munoz J, Kumar VA, Hamilton J, Pasche LJ, Langford LA, Taggart MW, Kamiya-Matsuoka C, Tummala S, Moulder S, Kurzrock R) J Clin Oncol 2013 Jul 10;31(20):e360-3       9 Citations
1Extensive cytoreductive surgery for appendiceal carcinomatosis: morbidity, mortality, and survival. (Wagner PL, Austin F, Maduekwe U, Mavanur A, Ramalingam L, Jones HL, Holtzman MP, Ahrendt SA, Zureikat AH, Pingpank JF, Zeh HJ, Bartlett DL, Choudry HA) Ann Surg Oncol 2013 Apr;20(4):1056-62       32 Citations
1Trastuzumab for the treatment of salivary duct carcinoma. (Limaye SA, Posner MR, Krane JF, Fonfria M, Lorch JH, Dillon DA, Shreenivas AV, Tishler RB, Haddad RI) Oncologist 2013;18(3):294-300       143 Citations
1The cost-effectiveness of neoadjuvant chemoradiation is superior to a surgery-first approach in the treatment of pancreatic head adenocarcinoma. (Abbott DE, Tzeng CW, Merkow RP, Cantor SB, Chang GJ, Katz MH, Bentrem DJ, Bilimoria KY, Crane CH, Varadhachary GR, Abbruzzese JL, Wolff RA, Lee JE, Evans DB, Fleming JB) Ann Surg Oncol 2013 Dec;20 Suppl 3:S500-8       55 Citations
1Impact of postmastectomy radiation on locoregional recurrence in breast cancer patients with 1-3 positive lymph nodes treated with modern systemic therapy. (Tendulkar RD, Rehman S, Shukla ME, Reddy CA, Moore H, Budd GT, Dietz J, Crowe JP, Macklis R) Int J Radiat Oncol Biol Phys 2012 Aug 01;83(5):e577-81       81 Citations
1Loco-regional therapy in patients with Milan Criteria-compliant hepatocellular carcinoma and short waitlist time to transplant: an outcome analysis. (Sourianarayanane A, El-Gazzaz G, Sanabria JR, Menon KV, Quintini C, Hashimoto K, Kelly D, Eghtesad B, Miller C, Fung J, Aucejo F) HPB (Oxford) 2012 May;14(5):325-32       11 Citations
1Ex vivo evaluation of preoperatively treated rectal cancer specimens of patients undergoing radical resection. (de la Fuente SG, Ludwig KA, Tyler DS, Mantyh CR) Ann Surg Oncol 2012 Jun;19(6):1954-8       2 Citations
1ACR Appropriateness Criteria® role of adjuvant therapy in the management of early stage cervical cancer. (Wolfson AH, Varia MA, Moore D, Rao GG, Gaffney DK, Erickson-Wittmann BA, Jhingran A, Mayr NA, Puthawala AA, Small W Jr, Yashar CM, Yuh W, Cardenes HR, American College of Radiology (ACR)) Gynecol Oncol 2012 Apr;125(1):256-62       14 Citations
1Adjuvant therapy for HER2+ breast cancer: practice, perception, and toxicity. (Rocque G, Onitilo A, Engel J, Pettke E, Boshoven A, Kim K, Rishi S, Waack B, Wisinski KB, Tevaarwerk A, Burkard ME) Breast Cancer Res Treat 2012 Jan;131(2):713-21       17 Citations
1Sequential vs. concurrent chemoradiation for stage III non-small cell lung cancer: randomized phase III trial RTOG 9410. (Curran WJ Jr, Paulus R, Langer CJ, Komaki R, Lee JS, Hauser S, Movsas B, Wasserman T, Rosenthal SA, Gore E, Machtay M, Sause W, Cox JD) J Natl Cancer Inst 2011 Oct 05;103(19):1452-60       933 Citations
2Radiation Therapy Oncology Group 0247: a randomized Phase II study of neoadjuvant capecitabine and irinotecan or capecitabine and oxaliplatin with concurrent radiotherapy for patients with locally advanced rectal cancer. (Wong SJ, Winter K, Meropol NJ, Anne PR, Kachnic L, Rashid A, Watson JC, Mitchell E, Pollock J, Lee RJ, Haddock M, Erickson BA, Willett CG) Int J Radiat Oncol Biol Phys 2012 Mar 15;82(4):1367-75       60 Citations
1Post-therapy pathologic stage and survival in patients with pancreatic ductal adenocarcinoma treated with neoadjuvant chemoradiation. (Estrella JS, Rashid A, Fleming JB, Katz MH, Lee JE, Wolf RA, Varadhachary GR, Pisters PW, Abdalla EK, Vauthey JN, Wang H, Gomez HF, Evans DB, Abbruzzese JL, Wang H) Cancer 2012 Jan 01;118(1):268-77       65 Citations
1Survival and quality of life of patients with resected pancreatic adenocarcinoma treated with adjuvant interferon-based chemoradiation: a phase II trial. (Katz MH, Wolff R, Crane CH, Varadhachary G, Javle M, Lin E, Evans DB, Lee JE, Fleming JB, Pisters PW) Ann Surg Oncol 2011 Dec;18(13):3615-22       18 Citations
1Comparative analysis of resection and liver transplantation for intrahepatic and hilar cholangiocarcinoma: a 24-year experience in a single center. (Hong JC, Jones CM, Duffy JP, Petrowsky H, Farmer DG, French S, Finn R, Durazo FA, Saab S, Tong MJ, Hiatt JR, Busuttil RW) Arch Surg 2011 Jun;146(6):683-9       151 Citations
1Adjuvant therapy for pancreatic cancer: a logical strategy in search of progress. (Evans DB, Wolff RA) Ann Surg Oncol 2011 May;18(5):1224-8       1 Citation
1Impact of neoadjuvant chemotherapy on breast reconstruction. (Hu YY, Weeks CM, In H, Dodgion CM, Golshan M, Chun YS, Hassett MJ, Corso KA, Gu X, Lipsitz SR, Greenberg CC) Cancer 2011 Jul 01;117(13):2833-41       40 Citations
1ACR Appropriateness Criteria® on Advanced Cervical Cancer Expert Panel on Radiation Oncology-Gynecology. (Gaffney DK, Erickson-Wittmann BA, Jhingran A, Mayr NA, Puthawala AA, Moore D, Rao GG, Small W Jr, Varia MA, Wolfson AH, Yashar CM, Yuh W, Cardenes HR) Int J Radiat Oncol Biol Phys 2011 Nov 01;81(3):609-14       56 Citations
1Intracystic papillary carcinoma of the breast: An in situ or invasive tumor? Results of immunohistochemical analysis and clinical follow-up. (Wynveen CA, Nehhozina T, Akram M, Hassan M, Norton L, Van Zee KJ, Brogi E) Am J Surg Pathol 2011 Jan;35(1):1-14       80 Citations
5Socioeconomic factors associated with adjuvant hormone therapy use in older breast cancer survivors. (Yen TW, Czypinski LK, Sparapani RA, Guo C, Laud PW, Pezzin LE, Nattinger AB) Cancer 2011 Jan 15;117(2):398-405       19 Citations
1Relation of mucous membrane alterations to oral intake during the first year after treatment for head and neck cancer. (Pauloski BR, Rademaker AW, Logemann JA, Lundy D, Bernstein M, McBreen C, Santa D, Campanelli A, Kelchner L, Klaben B, Discekici-Harris M) Head Neck 2011 Jun;33(6):774-9       17 Citations
2Carboplatin and docetaxel-induced acute pancreatitis: brief report. (Singh V, Devata S, Cheng YC) Int J Clin Oncol 2010 Dec;15(6):642-4       12 Citations
1Resistance to mammalian target of rapamycin inhibitor therapy in perivascular epithelioid cell tumors. (Subbiah V, Trent JC, Kurzrock R) J Clin Oncol 2010 Aug 20;28(24):e415       47 Citations
1Primary analysis of the phase II component of a phase I/II dose intensification study using three-dimensional conformal radiation therapy and concurrent chemotherapy for patients with inoperable non-small-cell lung cancer: RTOG 0117. (Bradley JD, Bae K, Graham MV, Byhardt R, Govindan R, Fowler J, Purdy JA, Michalski JM, Gore E, Choy H) J Clin Oncol 2010 May 10;28(14):2475-80       121 Citations
1Lymph node staging by positron emission tomography in cervical cancer: relationship to prognosis. (Kidd EA, Siegel BA, Dehdashti F, Rader JS, Mutch DG, Powell MA, Grigsby PW) J Clin Oncol 2010 Apr 20;28(12):2108-13       248 Citations
2Management of borderline resectable pancreatic cancer. (Lal A, Christians K, Evans DB) Surg Oncol Clin N Am 2010 Apr;19(2):359-70       9 Citations
1Trimodality therapy without a platinum compound for localized carcinoma of the esophagus and gastroesophageal junction. (Ajani JA, Correa AM, Walsh GL, Komaki R, Lee JH, Vaporciyan AA, Rice DC, Yao JC, Maru DM, Hofstetter WL, Phan AT, Swisher SG) Cancer 2010 Apr 01;116(7):1656-63       15 Citations
1Adjuvant interferon in high-risk melanoma: end of the era? (Janku F, Kurzrock R) J Clin Oncol 2010 Jan 10;28(2):e15-6; author reply e17-8       13 Citations
2The economic consequences of breast cancer adjuvant hormonal treatments. (Pezzin LE, O'Niel MB, Nattinger AB) J Gen Intern Med 2009 Nov;24 Suppl 2(Suppl 2):S446-50       23 Citations
2Recurrence of adrenal cortical carcinoma following resection: surgery alone can achieve results equal to surgery plus mitotane. (Grubbs EG, Callender GG, Xing Y, Perrier ND, Evans DB, Phan AT, Lee JE) Ann Surg Oncol 2010 Jan;17(1):263-70       125 Citations
1Polymorphisms of p16, p27, p73, and MDM2 modulate response and survival of pancreatic cancer patients treated with preoperative chemoradiation. (Chen J, Li D, Killary AM, Sen S, Amos CI, Evans DB, Abbruzzese JL, Frazier ML) Ann Surg Oncol 2009 Feb;16(2):431-9       40 Citations
1Adjuvant paclitaxel plus carboplatin compared with observation in stage IB non-small-cell lung cancer: CALGB 9633 with the Cancer and Leukemia Group B, Radiation Therapy Oncology Group, and North Central Cancer Treatment Group Study Groups. (Strauss GM, Herndon JE 2nd, Maddaus MA, Johnstone DW, Johnson EA, Harpole DH, Gillenwater HH, Watson DM, Sugarbaker DJ, Schilsky RL, Vokes EE, Green MR) J Clin Oncol 2008 Nov 01;26(31):5043-51       792 Citations
1Cisplatin, fluorouracil, interferon-alpha, and radiation as adjuvant therapy for resected pancreatic cancer: is there a future for this regimen and/or should we change our approach to research and treatment of patients with pancreatic cancer? (Pisters PW, Evans DB) Ann Surg 2008 Aug;248(2):152-3       4 Citations
1Preoperative gemcitabine-based chemoradiation for patients with resectable adenocarcinoma of the pancreatic head. (Evans DB, Varadhachary GR, Crane CH, Sun CC, Lee JE, Pisters PW, Vauthey JN, Wang H, Cleary KR, Staerkel GA, Charnsangavej C, Lano EA, Ho L, Lenzi R, Abbruzzese JL, Wolff RA) J Clin Oncol 2008 Jul 20;26(21):3496-502       644 Citations
1Adjuvant therapy for adenocarcinoma of the pancreas: analysis of reported trials and recommendations for future progress. (Wolff RA, Varadhachary GR, Evans DB) Ann Surg Oncol 2008 Oct;15(10):2773-86       51 Citations
1Does timing of androgen deprivation influence radiation-induced toxicity? A secondary analysis of radiation therapy oncology group protocol 9413. (Taussky D, Bae K, Bahary JP, Roach M 3rd, Lawton CA, Shipley WU, Sandler HM) Urology 2008 Nov;72(5):1125-9       11 Citations
1Role of adjuvant chemoradiation therapy in adenocarcinomas of the ampulla of vater. (Krishnan S, Rana V, Evans DB, Varadhachary G, Das P, Bhatia S, Delclos ME, Janjan NA, Wolff RA, Crane CH, Pisters PW) Int J Radiat Oncol Biol Phys 2008 Mar 01;70(3):735-43       64 Citations
1Thyroid function test abnormalities in patients with metastatic renal cell carcinoma treated with sorafenib. (Tamaskar I, Bukowski R, Elson P, Ioachimescu AG, Wood L, Dreicer R, Mekhail T, Garcia J, Rini BI) Ann Oncol 2008 Feb;19(2):265-8       123 Citations
1Future chemoradiation strategies in pancreatic cancer. (Crane CH, Varadhachary G, Pisters PW, Evans DB, Wolff RA) Semin Oncol 2007 Aug;34(4):335-46       28 Citations
1Impact of randomized clinical trial results in the national comprehensive cancer network on the use of tamoxifen after breast surgery for ductal carcinoma in situ. (Yen TW, Kuerer HM, Ottesen RA, Rouse L, Niland JC, Edge SB, Theriault RL, Weeks JC) J Clin Oncol 2007 Aug 01;25(22):3251-8       45 Citations
1Pilot study of regional, hepatic intra-arterial paclitaxel in patients with breast carcinoma metastatic to the liver. (Camacho LH, Kurzrock R, Cheung A, Barber DF, Gupta S, Madoff DC, Wallace MJ, Kim EE, Curley SA, Hortobagyi GN, Mavligit G) Cancer 2007 Jun 01;109(11):2190-6       29 Citations
1Delayed recovery after pancreaticoduodenectomy: a major factor impairing the delivery of adjuvant therapy? (Aloia TA, Lee JE, Vauthey JN, Abdalla EK, Wolff RA, Varadhachary GR, Abbruzzese JL, Crane CH, Evans DB, Pisters PW) J Am Coll Surg 2007 Mar;204(3):347-55       108 Citations
1Adjuvant therapy for renal cell carcinoma. (Jacobsohn KM, Wood CG) Semin Oncol 2006 Oct;33(5):576-82       36 Citations
1Should concomitant and adjuvant treatment with temozolomide be used as standard therapy in patients with anaplastic glioma? (Siker ML, Chakravarti A, Mehta MP) Crit Rev Oncol Hematol 2006 Nov;60(2):99-111       31 Citations
1Phase I trial evaluating the safety of bevacizumab with concurrent radiotherapy and capecitabine in locally advanced pancreatic cancer. (Crane CH, Ellis LM, Abbruzzese JL, Amos C, Xiong HQ, Ho L, Evans DB, Tamm EP, Ng C, Pisters PW, Charnsangavej C, Delclos ME, O'Reilly M, Lee JE, Wolff RA) J Clin Oncol 2006 Mar 01;24(7):1145-51       195 Citations
1Increased toxicity with gefitinib, capecitabine, and radiation therapy in pancreatic and rectal cancer: phase I trial results. (Czito BG, Willett CG, Bendell JC, Morse MA, Tyler DS, Fernando NH, Mantyh CR, Blobe GC, Honeycutt W, Yu D, Clary BM, Pappas TN, Ludwig KA, Hurwitz HI) J Clin Oncol 2006 Feb 01;24(4):656-62       128 Citations
1Colon cancer clinical practice guidelines in oncology. (Engstrom PF, Benson AB 3rd, Chen YJ, Choti MA, Dilawari RA, Enke CA, Fakih MG, Fuchs C, Kiel K, Knol JA, Leong LA, Ludwig KA, Martin EW Jr, Rao S, Saif MW, Saltz L, Skibber JM, Venook AP, Yeatman TJ, National Comprehensive Cancer Network) J Natl Compr Canc Netw 2005 Jul;3(4):468-91       56 Citations
1Phase II trial of postoperative adjuvant paclitaxel/carboplatin and thoracic radiotherapy in resected stage II and IIIA non-small-cell lung cancer: promising long-term results of the Radiation Therapy Oncology Group--RTOG 9705. (Bradley JD, Paulus R, Graham MV, Ettinger DS, Johnstone DW, Pilepich MV, Machtay M, Komaki R, Atkins J, Curran WJ, Radiation Therapy Oncology Group) J Clin Oncol 2005 May 20;23(15):3480-7       111 Citations
1Combined-modality treatment for operable pancreatic adenocarcinoma. (Pisters PW, Wolff RA, Crane CH, Evans DB) Oncology (Williston Park) 2005 Mar;19(3):393-404, 409; discussion 409-10, 412-6       24 Citations
1Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma--long-term results of phase III RTOG 85-31. (Pilepich MV, Winter K, Lawton CA, Krisch RE, Wolkov HB, Movsas B, Hug EB, Asbell SO, Grignon D) Int J Radiat Oncol Biol Phys 2005 Apr 01;61(5):1285-90       802 Citations
1Celecoxib and radiation therapy in non-small-cell lung cancer. (Gore E) Oncology (Williston Park) 2004 Dec;18(14 Suppl 14):10-4       22 Citations
1Treatment and recurrence patterns in endometrial stromal sarcomas and the relation to c-kit expression. (Geller MA, Argenta P, Bradley W, Dusenbery KE, Brooker D, Downs LS Jr, Judson PL, Carson LF, Boente MP) Gynecol Oncol 2004 Dec;95(3):632-6       50 Citations
1Subantimicrobial dose doxycycline enhances the efficacy of scaling and root planing in chronic periodontitis: a multicenter trial. (Preshaw PM, Hefti AF, Novak MJ, Michalowicz BS, Pihlstrom BL, Schoor R, Trummel CL, Dean J, Van Dyke TE, Walker CB, Bradshaw MH) J Periodontol 2004 Aug;75(8):1068-76       78 Citations
1Neoadjuvant therapy for resectable pancreatic cancer. (Raut CP, Evans DB, Crane CH, Pisters PW, Wolff RA) Surg Oncol Clin N Am 2004 Oct;13(4):639-61, ix       53 Citations
1Subantimicrobial dose doxycycline as adjunctive treatment for periodontitis. A review. (Preshaw PM, Hefti AF, Jepsen S, Etienne D, Walker C, Bradshaw MH) J Clin Periodontol 2004 Sep;31(9):697-707       115 Citations
4Subconjunctival antibiotics for acute postcataract extraction endophthalmitis--is it necessary? (Iyer MN, Han DP, Yun HJ, Eastwood D, Kim JE, Connor TB, Wirostko WJ, Dev S) Am J Ophthalmol 2004 Jun;137(6):1120-1       20 Citations
1Synchronous ovarian metastases at the time of laparotomy for colon cancer. (Wright JD, Powell MA, Mutch DG, Rader JS, Gibb RK, Huettner PC, Herzog TJ) Gynecol Oncol 2004 Mar;92(3):851-5       28 Citations
1Quality of care for breast cancer. (Nattinger AB) Med Care 2003 Mar;41(3):341-3       8 Citations
1Effect of a short course of neoadjuvant hormonal therapy on the response to subsequent androgen suppression in prostate cancer patients with relapse after radiotherapy: a secondary analysis of the randomized protocol RTOG 86-10. (Shipley WU, Lu JD, Pilepich MV, Heydon K, Roach M, Wolkov HB, Sause WT, Rubin P, Lawton CA, Machtay M) Int J Radiat Oncol Biol Phys 2002 Dec 01;54(5):1302-10       59 Citations
1ESPAC-1 trial of adjuvant therapy for resectable adenocarcinoma of the pancreas. (Evans DB, Hess KR, Pisters PW) Ann Surg 2002 Nov;236(5):694; author reply 694-6       27 Citations
1Ejaculatory function in stage T1 nonseminomatous germ cell tumors: retroperitoneal lymph node dissection versus surveillance--a decision analysis. (Langenstroer P, Rosen MA, Griebling TL, Thrasher JB) J Urol 2002 Oct;168(4 Pt 1):1396-401       5 Citations
1Therapeutic options and treatment of muscle invasive bladder cancer. (O'Connor RC, Alsikafi NF, Steinberg GD) Expert Rev Anticancer Ther 2001 Dec;1(4):511-22       7 Citations
1Localized adenocarcinoma of the pancreas: the rationale for preoperative chemoradiation. (Wayne JD, Abdalla EK, Wolff RA, Crane CH, Pisters PW, Evans DB) Oncologist 2002;7(1):34-45       80 Citations
1Multimodality management of localized pancreatic cancer. (Wayne JD, Wolff RA, Pisters PW, Evans DB) Cancer J 2001;7 Suppl 1:S35-46       12 Citations
1Preoperative chemoradiation therapy for pancreatic cancer. (Evans DB, Pisters PW) Surg Clin North Am 2001 Jun;81(3):709-13       3 Citations
1Preoperative chemoradiation for resectable and locally advanced adenocarcinoma of the pancreas. (Evans DB) J Gastrointest Surg 2001;5(1):2-5       18 Citations
1Neoadjuvant chemoradiotherapy for adenocarcinoma of the pancreas: treatment variables and survival duration. (Breslin TM, Hess KR, Harbison DB, Jean ME, Cleary KR, Dackiw AP, Wolff RA, Abbruzzese JL, Janjan NA, Crane CH, Vauthey JN, Lee JE, Pisters PW, Evans DB) Ann Surg Oncol 2001 Mar;8(2):123-32       315 Citations
1Subset analysis of RTOG 85-31 and 86-10 indicates an advantage for long-term vs. short-term adjuvant hormones for patients with locally advanced nonmetastatic prostate cancer treated with radiation therapy. (Horwitz EM, Winter K, Hanks GE, Lawton CA, Russell AH, Machtay M) Int J Radiat Oncol Biol Phys 2001 Mar 15;49(4):947-56       103 Citations
1Updated results of the phase III Radiation Therapy Oncology Group (RTOG) trial 85-31 evaluating the potential benefit of androgen suppression following standard radiation therapy for unfavorable prognosis carcinoma of the prostate. (Lawton CA, Winter K, Murray K, Machtay M, Mesic JB, Hanks GE, Coughlin CT, Pilepich MV) Int J Radiat Oncol Biol Phys 2001 Mar 15;49(4):937-46       369 Citations
1Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region. (Evans DB, Wolff RA, Hess KR) Ann Surg 2000 Nov;232(5):727       8 Citations
1Survival following treatment of a cardiac malignant fibrous histiocytoma. (Schena S, Caniglia A, Agnino A, Caruso G, Ferlan G) Chest 2000 Jul;118(1):271-3       19 Citations
1Factors correlated with progression-free survival after high-dose chemotherapy and hematopoietic stem cell transplantation for metastatic breast cancer. (Rowlings PA, Williams SF, Antman KH, Fields KK, Fay JW, Reed E, Pelz CJ, Klein JP, Sobocinski KA, Kennedy MJ, Freytes CO, McCarthy PL Jr, Herzig RH, Stadtmauer EA, Lazarus HM, Pecora AL, Bitran JD, Wolff SN, Gale RP, Armitage JO, Vaughan WP, Spitzer G, Horowitz MM) JAMA 1999 Oct 13;282(14):1335-43       65 Citations
1Chemoradiation for localized pancreatic cancer: another perspective. (Evans DB, Abbruzzese JL) Ann Surg Oncol 1999;6(1):4-7       4 Citations
1Preoperative chemoradiation strategies for localized adenocarcinoma of the pancreas. (Evans DB, Pisters PW, Lee JE, Bold RJ, Charnsangavej C, Janjan NA, Wolff RA, Abbruzzese JL) J Hepatobiliary Pancreat Surg 1998;5(3):242-50       42 Citations
1Neoadjuvant chemoradiation for adenocarcinoma of the pancreas. (Breslin TM, Janjan NA, Lee JE, Pisters PW, Wolff RA, Abbruzzese JL, Evans DB) Front Biosci 1998 Nov 01;3:E193-203       20 Citations
2Molecular metastases in stage I pancreatic cancer: improved survival with adjuvant chemoradiation. (Demeure MJ, Doffek KM, Komorowski RA, Redlich PN, Zhu YR, Erickson BA, Ritch PS, Pitt HA, Wilson SD) Surgery 1998 Oct;124(4):663-9       48 Citations
1Preoperative chemoradiation and pancreaticoduodenectomy for adenocarcinoma of the pancreas. (Miller AR, Pisters PW, Lee JE, Janjan NA, Abbruzzese JL, Evans DB) Hepatogastroenterology 1998;45(21):624-33       9 Citations
1Neoadjuvant chemoradiation for adenocarcinoma of the pancreas. (Miller AR, Robinson EK, Lee JE, Pisters PW, Chiao PJ, Lenzi RL, Abbruzzese JL, Evans DB) Surg Oncol Clin N Am 1998 Jan;7(1):183-97       20 Citations
1Neoadjuvant chemoradiation for extrahepatic cholangiocarcinoma. (McMasters KM, Tuttle TM, Leach SD, Rich T, Cleary KR, Evans DB, Curley SA) Am J Surg 1997 Dec;174(6):605-8; discussion 608-9       192 Citations
1Phase III trial of androgen suppression using goserelin in unfavorable-prognosis carcinoma of the prostate treated with definitive radiotherapy: report of Radiation Therapy Oncology Group Protocol 85-31. (Pilepich MV, Caplan R, Byhardt RW, Lawton CA, Gallagher MJ, Mesic JB, Hanks GE, Coughlin CT, Porter A, Shipley WU, Grignon D) J Clin Oncol 1997 Mar;15(3):1013-21       574 Citations
1p53 status and prognosis of locally advanced prostatic adenocarcinoma: a study based on RTOG 8610. (Grignon DJ, Caplan R, Sarkar FH, Lawton CA, Hammond EH, Pilepich MV, Forman JD, Mesic J, Fu KK, Abrams RA, Pajak TF, Shipley WU, Cox JD) J Natl Cancer Inst 1997 Jan 15;89(2):158-65       158 Citations
1Swallowing disorders in head and neck cancer patients treated with radiotherapy and adjuvant chemotherapy. (Lazarus CL, Logemann JA, Pauloski BR, Colangelo LA, Kahrilas PJ, Mittal BB, Pierce M) Laryngoscope 1996 Sep;106(9 Pt 1):1157-66       231 Citations
1Primary squamous cell carcinoma of the breast: sensitivity to cisplatinum-based chemotherapy. (Dejager D, Redlich PN, Dayer AM, Davis HL, Komorowski RA) J Surg Oncol 1995 Jul;59(3):199-203       66 Citations
1Absence of immunohistochemical metallothionein staining in bladder tumor specimens predicts response to neoadjuvant cisplatin, methotrexate and vinblastine chemotherapy. (Bahnson RR, Becich M, Ernstoff MS, Sandlow J, Cohen MB, Williams RD) J Urol 1994 Dec;152(6 Pt 2):2272-5       37 Citations
1Gallium nitrate delays the progression of microscopic disease in a human medulloblastoma murine model. (Whelan HT, Williams MB, Bajic DM, Flores RE, Schmidt MH, McAuliffe TL, Chitambar CR) Pediatr Neurol 1994 Jul;11(1):44-6       6 Citations
1DNA ploidy and P-glycoprotein expression as predictive factors of response to neoadjuvant chemotherapy for invasive bladder cancer. (Sandlow J, Cohen MB, Robinson RA, Dreicer R, Williams RD) Urology 1994 Jun;43(6):787-91       15 Citations
1Continuous split course irradiation for stage I and II Hodgkin's disease: 20 year experience at the Medical College of Wisconsin. (Rock DB, Schultz CJ, Murray KJ, Wilson JF, Cox JD) Radiother Oncol 1994 Mar;30(3):222-6       6 Citations
1Adjuvant radiotherapy and chemotherapy for biliary and pancreatic cancer. (Rich TA, Evans DB, Curley SA, Ajani JA) Ann Oncol 1994;5 Suppl 3:75-80       24 Citations
1Preoperative chemoradiation and pancreaticoduodenectomy for adenocarcinoma of the pancreas. (Evans DB, Rich TA, Byrd DR, Cleary KR, Connelly JH, Levin B, Charnsangavej C, Fenoglio CJ, Ames FC) Arch Surg 1992 Nov;127(11):1335-9       605 Citations
1Does more intensive therapy increase cures in acute leukemia? (Gale RP, Butturini A, Horowitz MM) Semin Hematol 1991 Jul;28(3 Suppl 4):93-4       2 Citations